LY9 and colorectal carcinoma: Consistent with our previous results, SLAMF3 knockdown increased the antitumor phagocytosis gene signature score of macrophages in liver metastases, particularly in C1qc+ TAMs (Figure 6D), a TAM subtype previously found to be enriched in both primary and liver metastatic lesions in CRC patients.[6] SLAMF3 knockdown increased the proportion of C1qc+ TAMs in liver metastases (Figure S8F).